Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease

M. J. Czaja, A. Geerts, J. Xu, P. Schmiedeberg, Y. Ju

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Considerable evidence suggests that monocytes/macrophages play a crucial role in the process of liver injury and repair. Recent investigations have focused on the function of various macrophage-produced cytokines in liver disease. Much is still unknown, however, about the mechanism of macrophage recruitment and activation during liver disease. To further define this process, the gene expression of the monocyte chemoattractant monocyte chemoattractant protein 1 (MCP-1) was examined in animal and human liver disease. MCP-1 mRNA was not found in normal rat liver by Northern blot analysis. After single-dose treatments with the hepatotoxins carbon tetrachloride and galactosamine, MCP-1 mRNA was detectable beginning at 2 and 4 h after treatment, respectively, and was expressed continuously until 60-72 h. During chronic carbon tetrachloride administration, MCP-1 mRNA levels were elevated for the entire 10 weeks of treatment with peak levels of expression occurring early (weeks 1-3) and late (weeks 8-10) in this model. Isolated liver cell fractions from rats treated for 3 weeks with carbon tetrachloride revealed the major cellular source of MCP-1 mRNA to be fat-storing or Ito cells, with some expression occurring in the endothelial cell fraction. Studies of potential inducers of hepatic MCP-1 expression showed that lipopolysaccharide, tumor necrosis factor-α, and interleukin-1α and β treatments all led to MCP-1 expression. Finally, studies of human liver samples revealed MCP-1 gene expression in nondiseased liver and greatly increased levels in livers from patients with fulminant hepatic failure. These data implicate MCP-1 from fat-storing cells as a modulator of the process of liver injury and further support a role for MCP-1 in the pathogenesis of human disease.

Original languageEnglish (US)
Pages (from-to)120-126
Number of pages7
JournalJournal of Leukocyte Biology
Volume55
Issue number1
StatePublished - 1994

Fingerprint

Chemokine CCL2
Poisons
Liver Diseases
Liver
Wounds and Injuries
Carbon Tetrachloride
Messenger RNA
Adipocytes
Monocytes
Macrophages
Gene Expression
Hepatic Stellate Cells
Galactosamine
Acute Liver Failure
Macrophage Activation
Chemotactic Factors
Therapeutics
Interleukin-1
Northern Blotting
Lipopolysaccharides

Keywords

  • liver injury
  • monocyte chemoattractant protein 1 (MCP-1)

ASJC Scopus subject areas

  • Cell Biology

Cite this

Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. / Czaja, M. J.; Geerts, A.; Xu, J.; Schmiedeberg, P.; Ju, Y.

In: Journal of Leukocyte Biology, Vol. 55, No. 1, 1994, p. 120-126.

Research output: Contribution to journalArticle

Czaja, MJ, Geerts, A, Xu, J, Schmiedeberg, P & Ju, Y 1994, 'Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease', Journal of Leukocyte Biology, vol. 55, no. 1, pp. 120-126.
Czaja, M. J. ; Geerts, A. ; Xu, J. ; Schmiedeberg, P. ; Ju, Y. / Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. In: Journal of Leukocyte Biology. 1994 ; Vol. 55, No. 1. pp. 120-126.
@article{935353ceb78541a8ae537256a3afb50e,
title = "Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease",
abstract = "Considerable evidence suggests that monocytes/macrophages play a crucial role in the process of liver injury and repair. Recent investigations have focused on the function of various macrophage-produced cytokines in liver disease. Much is still unknown, however, about the mechanism of macrophage recruitment and activation during liver disease. To further define this process, the gene expression of the monocyte chemoattractant monocyte chemoattractant protein 1 (MCP-1) was examined in animal and human liver disease. MCP-1 mRNA was not found in normal rat liver by Northern blot analysis. After single-dose treatments with the hepatotoxins carbon tetrachloride and galactosamine, MCP-1 mRNA was detectable beginning at 2 and 4 h after treatment, respectively, and was expressed continuously until 60-72 h. During chronic carbon tetrachloride administration, MCP-1 mRNA levels were elevated for the entire 10 weeks of treatment with peak levels of expression occurring early (weeks 1-3) and late (weeks 8-10) in this model. Isolated liver cell fractions from rats treated for 3 weeks with carbon tetrachloride revealed the major cellular source of MCP-1 mRNA to be fat-storing or Ito cells, with some expression occurring in the endothelial cell fraction. Studies of potential inducers of hepatic MCP-1 expression showed that lipopolysaccharide, tumor necrosis factor-α, and interleukin-1α and β treatments all led to MCP-1 expression. Finally, studies of human liver samples revealed MCP-1 gene expression in nondiseased liver and greatly increased levels in livers from patients with fulminant hepatic failure. These data implicate MCP-1 from fat-storing cells as a modulator of the process of liver injury and further support a role for MCP-1 in the pathogenesis of human disease.",
keywords = "liver injury, monocyte chemoattractant protein 1 (MCP-1)",
author = "Czaja, {M. J.} and A. Geerts and J. Xu and P. Schmiedeberg and Y. Ju",
year = "1994",
language = "English (US)",
volume = "55",
pages = "120--126",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "1",

}

TY - JOUR

T1 - Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease

AU - Czaja, M. J.

AU - Geerts, A.

AU - Xu, J.

AU - Schmiedeberg, P.

AU - Ju, Y.

PY - 1994

Y1 - 1994

N2 - Considerable evidence suggests that monocytes/macrophages play a crucial role in the process of liver injury and repair. Recent investigations have focused on the function of various macrophage-produced cytokines in liver disease. Much is still unknown, however, about the mechanism of macrophage recruitment and activation during liver disease. To further define this process, the gene expression of the monocyte chemoattractant monocyte chemoattractant protein 1 (MCP-1) was examined in animal and human liver disease. MCP-1 mRNA was not found in normal rat liver by Northern blot analysis. After single-dose treatments with the hepatotoxins carbon tetrachloride and galactosamine, MCP-1 mRNA was detectable beginning at 2 and 4 h after treatment, respectively, and was expressed continuously until 60-72 h. During chronic carbon tetrachloride administration, MCP-1 mRNA levels were elevated for the entire 10 weeks of treatment with peak levels of expression occurring early (weeks 1-3) and late (weeks 8-10) in this model. Isolated liver cell fractions from rats treated for 3 weeks with carbon tetrachloride revealed the major cellular source of MCP-1 mRNA to be fat-storing or Ito cells, with some expression occurring in the endothelial cell fraction. Studies of potential inducers of hepatic MCP-1 expression showed that lipopolysaccharide, tumor necrosis factor-α, and interleukin-1α and β treatments all led to MCP-1 expression. Finally, studies of human liver samples revealed MCP-1 gene expression in nondiseased liver and greatly increased levels in livers from patients with fulminant hepatic failure. These data implicate MCP-1 from fat-storing cells as a modulator of the process of liver injury and further support a role for MCP-1 in the pathogenesis of human disease.

AB - Considerable evidence suggests that monocytes/macrophages play a crucial role in the process of liver injury and repair. Recent investigations have focused on the function of various macrophage-produced cytokines in liver disease. Much is still unknown, however, about the mechanism of macrophage recruitment and activation during liver disease. To further define this process, the gene expression of the monocyte chemoattractant monocyte chemoattractant protein 1 (MCP-1) was examined in animal and human liver disease. MCP-1 mRNA was not found in normal rat liver by Northern blot analysis. After single-dose treatments with the hepatotoxins carbon tetrachloride and galactosamine, MCP-1 mRNA was detectable beginning at 2 and 4 h after treatment, respectively, and was expressed continuously until 60-72 h. During chronic carbon tetrachloride administration, MCP-1 mRNA levels were elevated for the entire 10 weeks of treatment with peak levels of expression occurring early (weeks 1-3) and late (weeks 8-10) in this model. Isolated liver cell fractions from rats treated for 3 weeks with carbon tetrachloride revealed the major cellular source of MCP-1 mRNA to be fat-storing or Ito cells, with some expression occurring in the endothelial cell fraction. Studies of potential inducers of hepatic MCP-1 expression showed that lipopolysaccharide, tumor necrosis factor-α, and interleukin-1α and β treatments all led to MCP-1 expression. Finally, studies of human liver samples revealed MCP-1 gene expression in nondiseased liver and greatly increased levels in livers from patients with fulminant hepatic failure. These data implicate MCP-1 from fat-storing cells as a modulator of the process of liver injury and further support a role for MCP-1 in the pathogenesis of human disease.

KW - liver injury

KW - monocyte chemoattractant protein 1 (MCP-1)

UR - http://www.scopus.com/inward/record.url?scp=0028117414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028117414&partnerID=8YFLogxK

M3 - Article

C2 - 8283136

AN - SCOPUS:0028117414

VL - 55

SP - 120

EP - 126

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 1

ER -